PHARMAC currently funds three vaccines against Streptococcus pneumoniae for specific groups of people – Pneumovax23, Synflorix and Prevenar13.
S. pneumoniae is one of several types of bacteria that can cause pneumonia. Prevenar13 and Pneumovax23 are used for a small group of people who are at high risk of pneumococcal disease because their immune system is compromised due to chronic health conditions or immune suppressant medicines. Synflorix is given to children as part of the routine childhood immunisation programme.
Funded vaccines available for those most at risk of pneumococcal disease
Pneumovax23 – Find out who is eligible
About 5,000 doses of this vaccine are administered to eligible patients each year.
Prevenar13 (PCV13) – Find out who is eligible
About 4,000 doses of this vaccine are administered to eligible patients each year.
Synflorix (PCV10) – Find out who is eligible
About 230,000 doses of this vaccine are administered to eligible children each year.
Who to contact
If you think you may qualify for a funded vaccination, talk to your health professional to find out if you should be vaccinated.
If you do not qualify for a funded vaccination, talk to your health professional about the options available to you.
If you are a vaccinator, please only use funded vaccine stock for eligible patients because this is the group most at risk from pneumococcal disease.
Last updated: 25 March 2020